Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700027119

Trial Profile

Clinical Trials Insight: 700027119

Phase of Trial: Phase II

Latest Information Update: 13 May 2008

At a glance

  • Drugs Verpasep caltespen (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors Nventa Biopharmaceuticals Corporation
  • Most Recent Events

    • 13 May 2008 Nventa have completed the significant design elements of this trial, according to an Nventa media release.
    • 24 Apr 2008 Nventa are currently finalising the trial design and plan to initiate enrolment by mid-2008.
    • 24 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top